Onco-Innovations Limited announced a significant study by the co-founders of its subsidiary, Inka Health Corp., which advances the real-world applicability of lung cancer clinical trial outcomes. The study, published in medRxiv, demonstrates a novel approach to aligning clinical trial results with real-world patient outcomes, particularly for non-small cell lung cancer. By incorporating external data and expert knowledge, the study’s model achieved a near-perfect match with real-world outcomes, highlighting its potential to improve clinical decision-making and expand patient access to innovative therapies. This advancement is crucial as it addresses the challenge of translating trial results to diverse populations, offering a scalable and scientifically rigorous methodology that could influence regulatory approvals and healthcare practices.

Onco-Innovations Limited operates in the healthcare industry, focusing on cancer research and drug development. Through its subsidiary, Inka Health Corp., the company leverages advanced real-world analytics to enhance the applicability of clinical trial outcomes to diverse patient populations globally.

Onco-Innovations Advances Real-World Applicability of Lung Cancer Trials

Onco-Innovations Limited announced a study by its subsidiary Inka Health Corp. that advances the real-world applicability of lung cancer clinical trials, particularly for non-small cell lung cancer. The study, published in medRxiv, uses external data and expert knowledge to align clinical trial results with real-world patient outcomes, improving clinical decision-making and expanding access to therapies.